Poseida Therapeutics Inc (PSTX)

NASDAQ
6.440
+0.080(+1.26%)
  • Volume:
    13,634
  • Bid/Ask:
    6.400/6.440
  • Day's Range:
    6.390 - 6.470

PSTX Overview

Prev. Close
6.36
Day's Range
6.39-6.47
Revenue
-
Open
6.36
52 wk Range
6.2-13.94
EPS
-2.56
Volume
13,634
Market Cap
396.47M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
198,644
P/E Ratio
-
Beta
-
1-Year Change
-41.27%
Shares Outstanding
62,338,597
Next Earnings Date
Nov 18, 2021
What is your sentiment on Poseida Therapeutics Inc?
or
Vote to see community's results!

Poseida Therapeutics Inc News

Poseida Therapeutics Inc Analysis

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesNeutralSellNeutralSellSell
Technical IndicatorsBuyNeutralStrong BuyStrong SellStrong Sell
SummaryNeutralNeutralBuyStrong SellStrong Sell

Poseida Therapeutics Inc Company Profile

Poseida Therapeutics Inc Company Profile

Employees
220

Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company is developing P-BCMA-101, an autologous chimeric antigen receptor T cell (CAR-T) targeting B cell maturation antigen that is in Phase II clinical trial; P-PSMA-101, an autologous CAR-T product candidate for the treatment of patients with metastatic castrate resistant prostate cancer (mCRPC) is in Phase I clinical trials; P-BCMA-ALLO1, an allogeneic CAR-T product candidate to treat relapsed/refractory multiple myeloma patients; P-MUC1C-ALLO1, an allogeneic CAR-T product candidate for multiple solid tumor indications; and P-PSMA-ALLO1, an allogeneic CAR-T product candidate for treating mCRPC. It is also developing P-OTC-101, a liver-directed gene therapy for the treatment of ornithine transcarbamylase; and P-MMUT-101, a liver-directed gene therapy for the treatment of methylmalonic acidemia. In addition, the company is developing a portfolio of allogeneic dual CAR product candidates. It has a research collaboration and license agreement with Takeda Pharmaceutical Company Limited. The company was incorporated in 2014 and is headquartered in San Diego, California.

Read More
  • Sigh
    0
    Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
    Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.